Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

24 results about "Retinol binding protein" patented technology

Retinol-binding proteins (RBP) are a family of proteins with diverse functions. They are carrier proteins that bind retinol. Assessment of retinol-binding protein is used to determine visceral protein mass in health-related nutritional studies.

Low-temperature storage refrigerator for retinol binding protein

The utility model relates to the technical field of retinol binding protein, and provides a retinol binding protein low-temperature storage refrigerator which comprises a low-temperature refrigerator body, a plurality of inserting grooves are sequentially formed in the two sides of the inner wall of the low-temperature refrigerator body from top to bottom, mounting plates are inserted into the inserting grooves, two fixing rods are fixedly installed on the tops of the mounting plates, and the two fixing rods are connected with the inserting grooves. The outer side wall of the fixing rod is sleeved with a sleeve, the outer side wall of the sleeve is fixedly provided with a storage disc and a tray, the storage disc is located on the upper side of the tray, one corresponding sealing assembly is manually opened, then the storage disc or the tray is manually rotated, and therefore the storage disc and the tray can rotate under the cooperation of the fixing rod and the sleeve. According to the low-temperature refrigerator, the test tubes on the storage disc and the tray in the low-temperature refrigerator body can be conveniently taken by personnel, so that the personnel can be prevented from touching other test tubes when taking the test tubes, meanwhile, the refrigeration temperature of the other test tubes can be ensured, and the refrigeration effect is effectively ensured.
Owner:CHENGDU CORMORANT BIOTECHNOLOGY CO LTD

Novel co-drug, co-administration, and sequential administration of bispecific RBP4 / TTR ligand and c20-d3-retinol for elimination of mechanism-based ocular adverse effects in treating macular degeneration and TTR amyloidosis

PCT designated stage expiredWO2024263782A2Group 4/14 element organic compoundsSenses disorderRetinoidRetinaldehyde
New therapies for macular degeneration and TTR amyloidosis are provided based on a co-drug that represents a conjugate of two distinct chemical entities as well as co- administration and sequential administration of the two chemical entities. The first component ("bispecific RBP4 / TTR ligand") is a chemical entity that engages TTR ( transthyretin) and RBP4 ( retinol binding protein 4 ) of the RBP4 -TTR complex, which is involved in delivery of retinol to the retina. This component reduces traffic of retinol from circulation to the retina and provides stabilization of TTR tetramers. The second component ("C20-D3-visual-chromophore-producing compound" ) is a C20 -D3 -modified retinoid or carotenoid that upon metabolism in a mammal can eventually produce a C20-D3 visual chromophore that represents C20 -D3- 9-cis-retinaldehyde or C20-D3-11-cis-retinaldehyde in the retina. Deuteration at the C20 position reduces the formation of lipofuscin bisretinoid while other functions ( such as providing a precursor for in vivo synthesis of the visual chromophore, 11-cis-retinaldehyde ) are not reduced.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK +1

RBP4 antagonists for treatment and prevention of non-alcoholic fatty liver disease and gout

The present invention provides a method for treating non-alcoholic fatty liver disease (NAFLD) in a subject suffering from the disease, the method comprising administering to the subject a pharmaceutical composition comprising an amount of a compound effective for treating the subject, thereby treating the subject, the compound is a retinol binding protein 4 (RBP4) antagonist which is a non-retinol-like retinol binding protein 4 (RBP4) antagonist. The present invention provides a method for treating gout in a subject suffering from this disease, the method comprising administering to the subject a pharmaceutical composition comprising an amount of a compound effective for treating the subject, the compound being a retinol binding protein 4 (RBP4) antagonist.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK

Retinol binding protein detection kit and preparation method thereof

The invention discloses a retinol binding protein detection kit and a preparation method thereof. The detection kit comprises a reagent R1 and a reagent R2. The reagent R1 comprises an oxidizing agent and is beneficial to maintaining the structural stability of the retinol binding protein. And the R2 reagent comprises latex microspheres loaded with a retinol binding protein antibody. According to the present invention, the antibody directional coupling technology is adopted, such that the stable thioether bond is formed between the retinol binding protein antibody and the latex microsphere, the retinol binding protein antibody is coupled to the latex microsphere, the antibody is connected with the microsphere through the Fc region, and the Fab region extends outward so as not to affect the antibody active region configuration, and the efficient combination with the sample antigen is achieved;
Owner:ZHEJIANG YILIKANG BIOLOGICAL TECH CO LTD

Compositions and methods for diagnosing and / or treating chronic kidney disease

PendingCN121569194AOrganic active ingredientsDisease diagnosisNephrosisCOAGULATION FACTOR X
Compositions and methods use one or more feline circulating proteins as markers for early chronic kidney disease (CKD) to diagnose and / or treat CKD. A method of diagnosing chronic kidney disease (CKD) in a feline can include measuring an amount of each of at least one circulating protein from the feline. The at least one circulating protein is one or more of adiponectin (ADIPOQ), antibacterial peptide (CAMP), kinetin-like protein (KIF12), plasma retinol binding protein (RBP4), Ig-like domain containing protein (ZKSCAN1), blood coagulation factor X (F10), fibronectin (FN1), and mixtures thereof. The method further comprises comparing the amount of each of the at least one circulating protein from the feline to a respective predetermined value or a respective predetermined range. The method further comprises diagnosing the feline as having or not having early CKD based on the comparison.
Owner:SOCIETE DES PRODUITS NESTLE SA

Yarrowia lipolytica engineering bacterium for producing retinol, retinyl ester and derivatives of retinol and retinyl ester as well as fermentation method and application of Yarrowia lipolytica engineering bacterium

PendingCN119979360AFungiMicroorganism based processesRetinol dehydrogenasePalmitates
The invention belongs to the technical field of microorganisms and fermentation engineering, and particularly relates to Yarrowia lipolytica engineering bacteria for producing retinol, retinyl ester and derivatives thereof as well as a fermentation method and application of the Yarrowia lipolytica engineering bacteria. Specifically, firstly, yarrowia lipolytica is modified, beta-carotene 15, 15 '-oxygenase and retinol dehydrogenase from different host sources are screened, the copy number of key genes in a metabolic pathway is adjusted, the metabolic flux of a precursor is enhanced, the yield of retinol is increased, and meanwhile, the yield of retinol is increased by optimizing culture conditions. Therefore, the content of retinol is increased, and direct biosynthesis of retinol palmitate is finally realized by adjusting a carbon source and introducing retinol binding protein. In a word, a yarrowia lipolytica platform for efficiently synthesizing the retinol and the retinol ester is designed, and a foundation is laid for sustainable industrial production of the retinol and the retinol ester, so that the yarrowia lipolytica has excellent practical application value and application prospect.
Owner:SHANDONG UNIV

Stable composite special protein control product and preparation method thereof

The invention relates to the technical field of medical examination, in particular to a stable compound type special protein control product and a preparation method thereof.The preparation method comprises the steps that purified water is taken, a buffer solution, a protective agent, a first stabilizer, a chelating agent, C-reactive protein, antistreptolysin O, rheumatoid factors and retinol binding protein are sequentially added, the mixture is fully stirred till being completely dissolved, and the stable compound type special protein control product is obtained; putting into a constant-temperature box for aging to obtain a dissolving solution; taking out the dissolved solution, standing to room temperature, and filtering by using a peristaltic pump and a bag type filter to obtain a filtrate; and sequentially adding a second stabilizer, cystatin C protein, a third stabilizer, an ion balance agent, lipoprotein (a) and a preservative into the filtrate, and adjusting the pH value to obtain the composite special protein control product. The method can be used for quality control of biochemical item detection processes of retinol binding protein, cystatin C protein, C-reactive protein, antistreptolysin 'O', rheumatoid factors and lipoprotein (a) at the same time.
Owner:URIT MEDICAL ELECTRONICS CO LTD

A liquid chromatography method for simultaneous detection of multiple proteins

The application provides a liquid chromatography analysis method for simultaneously detecting multiple proteins, which adopts anion liquid chromatography with non-porous resin as a stationary phase, a Tris gradient eluent phase containing Cl ‑ , the non-porous resin is bonded with a hydrophilic polymer nanolayer on the surface, the nanolayer is modified with a quaternary ammonium group, the proteins have different isoelectric points, and the pH of the eluent phase is greater than the isoelectric points of the proteins. The application can simultaneously separate and purify multiple proteins through one-time anion liquid chromatography, and can approximately achieve baseline separation. The overall method is simple, economical, efficient, and environmentally friendly for the mobile phase, and is suitable for the separation of proteins with different isoelectric points, and is particularly suitable for the detection and separation of proteins such as albumin, transferrin, retinol binding protein, beta 2 microglobulin and alpha 1 microglobulin in urine.
Owner:SUZHOU SEPAX TECHNOLOGIES INC

Methods for selecting patients for reperfusion therapy

ActiveCN114041058BDisease diagnosisBiological testingReperfusion therapyMyocardial reperfusion
The present invention relates to a method for selecting a patient suffering from a stroke for reperfusion therapy, based on determining the levels of retinol binding protein 4 (RBP4) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) in an isolated sample of said patient. The present invention also relates to a method for differentiating between ischemic stroke and hemorrhagic stroke, and to a kit comprising reagents for performing said methods.
Owner:FUNDACIÓ HOSPITAL UNIVERSITARI VALL D HEBRON - INSTITUT DE RECERCA

Immunogen as well as preparation method and application thereof

The invention discloses an immunogen as well as a preparation method and application thereof. The immunogen is a fusion protein and is obtained by adding a connecting sequence to carry out fusion expression on three amino acid sites, namely 21 and 22, 79 and 80, 130 and 131 of a hepatitis B carrier protein with a nucleotide sequence shown as SEQ ID No.2. The amino acid sequence of the immunogen is as shown in SEQ ID No. 4. The immunogen forms a homologous multimer by using the main assembly characteristic of the hepatitis B core antigen, so that the RBP antigens are orderly displayed on the surface of the hepatitis B core antigen multimer, and the immunogenicity of the target protein can be greatly improved. Therefore, the percent of pass of the immunogen serum antibody prepared by the invention is 70% and is far higher than that of a recombinant retinol binding protein monomer, and the immunogen serum antibody has good immunogenicity and is more beneficial to early diagnosis of liver and kidney diseases.
Owner:SHANGHAI JIEMEN BIO TECH

Selective RBP4 antagonists and c20-d3-retinol for the treatment of macular degeneration, nonalcoholic fatty liver disease (NAFLD), and gouty arthritis (gout)

PendingCN122341366ADiseaseRetinoid
Based on co-drugs representing two different chemical entities, and the co-administration and sequential administration of said two chemical entities, novel therapies are provided for macular degeneration, non-alcoholic fatty liver disease (NAFLD), and gouty arthritis (gout). The first component (“Selective RBP4 Antagonist”) is a chemical entity that interacts with RBP4 (retinol-binding protein 4), part of the RBP4-TTR (transthyretin) complex that delivers retinol to the retina. This component reduces the transport of retinol from circulation to the retina. The second component (“C20-D3-Visual Chromosome-Generating Compound”) is a C20-D3-modified retinoid or carotenoid that, when metabolized in mammals, ultimately produces a C20-D3 visual chromophore in the retina representing either C20-D3-9-cis-retinal or C20-D3-11-cis-retinal. Deuteration at the C20 position reduces the formation of lipofuscin biretinol, while other functions (such as providing a precursor for the in vivo synthesis of visual chromophore 11-cis-retinaldehyde) are not reduced.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK +1

Method of selecting patient for reperfusion therapy

PendingJP2025143285ADisease diagnosisBiological testingGlial Fibrillary Acid ProteinGlial fibrillar acidic protein
To provide a method of selecting a patient suffering stroke for a reperfusion therapy, a method of differentiating ischemic stroke from hemorrhagic stroke, and to kits comprising reagents for implementing the methods.SOLUTION: A method of selecting a patient suffering stroke for a reperfusion therapy is provided, the method comprising determining the level of retinol-binding protein-4 (RBP4) and the level of N-terminal fragment of B-type natriuretic peptide (NT-proBNP) in an isolated sample of a patient. The method further comprises determining the level of glial fibrillary acid protein (GFAP) in the isolated sample.SELECTED DRAWING: Figure 3
Owner:FUNDACIÓ HOSPITAL UNIVERSITARI VALL D HEBRON - INSTITUT DE RECERCA

Method for selecting a patient for a reperfusion therapy

ActiveUS12681022B2Reperfusion therapyMyocardial reperfusion
The invention relates to a method for selecting a patient suffering stroke for a reperfusion therapy based on determining the level of retinol binding protein-4 (RBP4) and N-terminal fragment of B-type natriuretic peptide (NT-proBNP) in an isolated sample of said patient. The invention also relates to a method of differentiating ischemic stroke from haemorrhagic stroke and to kits comprising reagents to carry out the methods.
Owner:FUNDACIÓ HOSPITAL UNIVERSITARI VALL D HEBRON - INSTITUT DE RECERCA

Novel co-drug, co-administration, and sequential administration of selective TTR ligand and c20-d3-retinol for elimination of mechanism-based ocular adverse effects in treating macular degeneration and TTR amyloidosis

PCT designated stage expiredWO2024263751A2Group 4/14 element organic compoundsSenses disorderRetinoidRetinaldehyde
New therapies for macular degeneration and TTR amyloidosis are provided based on a co-drug that represents a conjugate of two distinct chemical entities as well as co- administration and sequential administration of the two chemical entities. The first component ("selective TTR ligand") is a chemical entity that engages TTR (transthyretin) of the RBP4 (retinol binding protein 4) -TTR complex, which is involved in delivery of retinol to the retina. This component reduces traffic of retinol from circulation to the retina and provides stabilization of TTR tetramers. The second component ("C20-D3-visual- chromophore-producing compound") is a C20-D3-modified retinoid or carotenoid that upon metabolism in a mammal can eventually produce a C20-D3 visual chromophore that represents C20-D3-9-cis-retinaldehyde or C20-D3-11-cis-retinaldehyde in the retina. Deuteration at the C20 position reduces the formation of lipofuscin bisretinoid while other functions (such as providing a precursor for in vivo synthesis of the visual chromophore, 11-cis-retinaldehyde) are not reduced.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK +1

Retinol binding protein incubator

The utility model relates to the technical field of incubators, and provides a retinol binding protein incubator which comprises an incubator body, a motor and a fixing support are fixedly installed at the bottom of the incubator body respectively, the motor is located on the inner side of the fixing support, a rotating rod is rotatably installed on the inner bottom wall of the incubator body, and the output end of the motor is fixedly connected with the rotating rod. A plurality of T-shaped discs are sequentially arranged on the outer side wall of a rotating rod from top to bottom, the rotating rod is driven by a motor to rotate, and then the rotating rotating rod drives the T-shaped discs to rotate under the cooperation of a locking assembly and an inserting hole, so that a culture dish to be taken can be moved to the right front, personnel can take the culture dish conveniently, and the working efficiency is improved. Furthermore, all the culture dishes do not need to be taken out from the box body, the influence on other culture dishes can be reduced, and meanwhile, when the motor drives the T-shaped disc to rotate, objects in the culture dishes shake under the action of centrifugal force, so that nutrient substances in a culture solution can be ensured to be uniformly distributed, and the growth and metabolic activity of cells are promoted.
Owner:CHENGDU CORMORANT BIOTECHNOLOGY CO LTD

Pharmaceutical composition for preventing or treating fibrotic diseases

The present invention relates to a novel fusion protein of albumin and retinol-binding protein, which can be used for preventing or treating fibrotic diseases occurring in the liver, pancreas, lungs, and the like. The fusion protein of the present invention can prevent or treat fibrotic diseases by inhibiting activation of stellate cells that cause tissue fibrosis or by inducing reversion of the activated state.
Owner:KOREA UNIV RES & BUSINESS FOUND

Retinol binding protein detection kit as well as preparation method and application thereof

The invention belongs to the technical field of biological detection, and particularly relates to a retinol binding protein detection kit as well as a preparation method and application thereof. The kit provided by the invention comprises a reagent R1, a reagent R2 and a standard substance, the composition and the concentration of each component are strictly limited, a calibration curve is drawn by using the standard substance with known concentration and the concentration, a sample with unknown concentration can be measured to obtain a signal value, and the corresponding concentration of the measured sample is obtained according to the corresponding signal value on the standard curve. The retinol binding protein detection kit provided by the invention is low in cost, simple in production process, convenient to operate, high in specificity, high in sensitivity and good in stability, can realize simultaneous detection of blood and urine, and can simultaneously detect the RBP content in the blood and the urine. The result of the embodiment shows that the linear range can reach 0.5-200mg / L in a blood mode, and the linear range can reach 0.3-20mg / L in a urine mode.
Owner:SHANGHAI ZHICHENG BIOTECHNOLOGY CO LTD

Formulations of RBP4 inhibitors and methods of use

To provide compositions for effective treatment of retinol binding protein 4 (RBP4)-related visual diseases and disorders.SOLUTION: A pharmaceutical composition comprising (i) a compound of formula (I), or a pharmaceutically acceptable salt, crystal, solvate, polymorph, prodrug, metabolite, N-oxide, stereoisomer, or isomer thereof, and (ii) a dispersion polymer.SELECTED DRAWING: Figure 2
Owner:BELIGHT BIO LLC

Novel co-drug, co-administration, and sequential administration of selective RBP4 antagonist and c20-d3-retinol for elimination of mechanism-based ocular adverse effects in treating macular degeneration, non-alcoholic fatty liver disease (NAFLD), and gouty arthritis (GOUT)

PCT designated stage expiredWO2024263790A2Senses disorderOrganic chemistryRetinoidRetinaldehyde
New therapies for macular degeneration, non-alcoholic fatty liver disease (NAFLD), and gouty arthritis (gout) are provided based on a co-drug that represents a conjugate of two distinct chemical entities as well as co-administration and sequential administration of the two chemical entities. The first component ("selective RBP4 antagonist") is a chemical entity that engages RBP4 (retinol binding protein 4) of the RBP4-TTR (transthyretin) complex, which is involved in delivery of retinol to the retina. This component reduces traffic of retinol from circulation to the retina. The second component ("C20-D3- visual- chromophore-producing compound") is a C20-D3-modified retinoid or carotenoid that upon metabolism in a mammal can eventually produce a C20-D3 visual chromophore that represents C20-D3-9-cis-retinaldehyde or C20-D3-11-cis-retinaldehyde in the retina. Deuteration at the C20 position reduces the formation of lipofuscin bisretinoid while other functions (such as providing a precursor for in vivo synthesis of the visual chromophore, 11-cis-retinaldehyde) are not reduced.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK +1

Compositions and methods for the delivery of nucleic acids

A nanosized complex includes a nucleic acid and a compound comprising formula (I):wherein R1 is an alkylamino group or a group containing at least one aromatic group;R2 and R3 are independently an aliphatic group or hydrophobic group;R4 and R5 are independently H, a substituted or unsubstituted alkyl group, an alkenyl group, an acyl group, or an aromatic group, or a polymer, a targeting group, a detectable moiety, or a linker, or a combination thereof, and at least one of R4 and R5 includes a retinoid or retinoid derivative that targets and / or binds to an interphotoreceptor retinoid binding protein;a, b, c, and d are independently an integer from 1 to 10; and pharmaceutically acceptable salts thereof.
Owner:CASE WESTERN RESERVE UNIV

Solid nanopore-based protein detection system and application thereof

The invention relates to a solid nanopore-based protein detection system and application thereof, and belongs to the technical field of protein detection. The invention discloses a protein detection system based on solid nanopores. The protein detection system comprises detection equipment and a detection reagent, the detection equipment comprises an electrode cavity, an electrode and a data acquisition system; the electrode cavity comprises a cis-type cavity and a trans-type cavity, a silicon nitride chip is arranged between the cis-type cavity and the trans-type cavity, and the cis-type cavity and the trans-type cavity are connected through nanopores in the silicon nitride chip; electrodes are arranged in the cis-type cavity and the trans-type cavity and are connected with a data acquisition system; the detection reagent contains a double-antibody sandwich paired retinol binding protein 4 monoclonal antibody and a retinol binding protein 4 monoclonal antibody obtained by taking retinol binding protein 4 as an immunogen to immunize a mouse. The invention provides a novel high-sensitivity, rapid and trace system and method. The system and the method have the advantages of single molecule sensitivity, real-time detection, low sample quantity requirement and the like.
Owner:GUANGZHOU INSIGHT TECH CO LTD

Use of a reagent for detecting RBP1 for the manufacture of a kit for diagnosing atrial fibrillation

The application provides a reagent for detecting RBP1 for preparing a kit for diagnosing atrial fibrillation, difference genes of atrial fibrillation patients and non-atrial fibrillation patients are obtained through weight gene co-expression network analysis (WGCNA), and RT-qPCR is used for verification in human peripheral blood samples. Peripheral blood leukocyte extraction: 3-5ml of venous blood is taken, EDTA anticoagulation is carried out, and centrifugation is carried out at 2500rpm for 10min; the upper plasma is carefully sucked and is divided into 3 0.5ml centrifuge tubes; 3 times the volume of hemolytic liquid is added into the blood cells, and shaking is carried out, ice bath is carried out for 15min; 2500rpm centrifugation is carried out for 10min, and the supernatant is discarded. The RBP1 detection method can be used as a biomarker to assist the diagnosis of atrial fibrillation. Retinol binding protein 1 is a protein encoded by the CRABP1 gene. It binds with high affinity to retinol and retinoids, protects retinoids from nonspecific oxidation, and delivers retinoids to specific enzymes. Changes in RBP1 gene expression will affect retinoic acid production, cell proliferation and microenvironment of epithelial cells. Blood biomarker sampling is simple and low in price.
Owner:THE SIXTH MEDICAL CENT OF THE CHINESE PEOPLES LIBERATION ARMY GENERAL HOSPITAL

An analysis method for simultaneously detecting multiple proteins in urine

The application provides an analysis method for simultaneously detecting multiple proteins in urine, which sequentially filters the urine through a hydrophilic MCE filter membrane, a volume exclusion gel column containing dextran, and a high performance anion exchange chromatography column containing a non-porous resin filler with a functional group of + (CH3)3, to remove impurities and concentrate target proteins, and then uses high performance anion exchange chromatography of the non-porous resin filler with a functional group of + (CH3)3 to perform detection analysis. The method is simple in operation and few in steps, and can quickly and accurately perform qualitative and quantitative analysis on proteins such as albumin, transferrin, retinol binding protein, beta 2 microglobulin and alpha 1 microglobulin in urine.
Owner:SUZHOU SEPAX TECHNOLOGIES INC

Method for improving ovum in-vitro maturation quality and blastocyst quality and application thereof

The invention belongs to the technical field of biology, and particularly relates to a method for improving the in-vitro maturation quality of ovum and the blastocyst quality and application of the ovum and blastocyst quality. The invention discloses beta-sodium glycerophosphate pentahydrate. According to the preparation, at least one of the retinol binding protein and the sodium beta-glycerophosphate pentahydrate is added to improve the cleavage rate and blastocyst rate of an in-vitro embryo, the oxidation resistance of an oocyte and the like, so that the maturation quality of the in-vitro oocyte and the development potential of the in-vitro embryo are remarkably improved, and the application prospect is wide.
Owner:CHINA AGRI UNIV